Navigation Links
GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
Date:9/25/2007

ST. JOSEPH, Mich., Sept. 25 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb (NYSE: BMY) has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo products to overlay their own internal interaction data in the context of manually curated pathways for more elucidation.

"Bristol Myers Squibb is very important to GeneGo as they have excellent scientists who we have been collaborating with," said Julie Bryant, GeneGo's VP of Business Development. "We plan to continue this collaborative spirit over the next few years."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology
'/>"/>

SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , Md. and BALTIMORE , ... (BHI), a regional private-public partnership focusing on ... early-stage funding in Central Maryland ... Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for ... National Heart, Lung and Blood Institute ...
(Date:5/20/2013)... 2013 Rhythm announced today the results of ... company,s novel ghrelin agonist for the treatment of diabetic ... that RM-131 significantly accelerates early gastric emptying and reduces ... with diabetic gastroparesis. The findings were presented at the ... and recently published in Clinical Gastroenterology ...
(Date:5/20/2013)... WILMINGTON, Del. (PRWEB) May 20, 2013 ... named 14 young faculty members to its 2013 ... three years, the company will provide this outstanding ... their work in advancing basic science to meet ... is designed to help promising young and untenured ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In Early ... the field of biotoxin related illnesses , announced his ... country able to advance his protocol for treating Chronic ... became the third physician to achieve certification in the ... Physicians, able to practice the Shoemaker Protocol in other ...
Breaking Biology Technology:BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2
... Wisconsin has some catching up to do even among ... investment, according to the latest Midwest Health Care Venture ... publicly disclosed investments in 12 states or regions in ... than three times the investment Wisconsin had. , ,These ...
... we continue to review biotech results for 2005 and try to ... , ,Another research tool I have always found useful for this ... the biotech industry. One of the things I like about Burrill ... the biotech industry's biggest cheerleaders. , ,Another aspect is that he ...
... The University of Wisconsin-Madison MBA program was ... and 19th among U.S. public university programs by the ... list in 2005. , ,These rankings are based on ... Financial Times compiled data provided by the schools and ...
Cached Biology Technology:2005 was a tough year for U.S. biotech financing 22005 was a tough year for U.S. biotech financing 32005 was a tough year for U.S. biotech financing 42005 was a tough year for U.S. biotech financing 5
(Date:5/17/2013)... Research Foundation announced a new grant that intends to ... one of today,s most exciting areas of science, and ... Awards Panel selected Andrew T. Chan, MD, MPH and ... School, Boston, as the 2013 AGA-Elsevier Gut Microbiome Pilot ... funding, commencing in July 2013, to test the overarching ...
(Date:5/17/2013)... interaction of a group of proteins in the brain ... a new target that could increase cell survival. , ... of Biochemistry and published in the EMBO journal ... lead to new therapies for stroke and other brain ... the team which identified a protein, known as SUMO, ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
... A team of researchers from the University of Houston ... to develop improved screening methods to detect a potentially ... Texas. Specifically, the research team looked at ... increasingly resistant to most drugs of last resort. Commonly ...
... which plants space out the pores through which they breathe ... according to John Innes Centre scientists. Plant pores, ... 400 million years ago, they helped plants conquer the land. ... water vapour as part of the Earth,s carbon and water ...
... Stem cells show great potential to enable treatments for ... also as research tools. One of the greatest problems slowing ... purifying cell mixtures, for instance to remove stem cells that ... treatments. But a group of Scripps Research scientists, working with ...
Cached Biology News:UH researchers work to develop screening method for superbug 2The breathtaking dance of plants 2Scripps Research team overcomes major obstacle for stem cell therapies and research 2Scripps Research team overcomes major obstacle for stem cell therapies and research 3
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Biology Products: